This international project aims to calculate the drug survival of omalizumab in a large multicenter daily practice cohort of patients with CU treated in UCARE centers, and identify determinants of drug survival in this overall international population differentiated by reason of discontinuation.
Contact: H.Rockmann@umcutrecht.nl
GA²LEN coordinating Office
Charité Universitätsmedizin Berlin
Luisenstr. 2-5
10117 Berlin, Germany
UCARE office
Laura Schwenner
